Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
European Journal of Haematology
|
September 6, 2019
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Charlotte Gran, Katarina Uttervall, Johanna Borg Bruchfeld, et al.
European Journal of Haematology
|
October 15, 2013
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients
Johan Lund, Katarina Uttervall, Johan Liwing, et al.
European Journal of Haematology
|
June 25, 2019
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Katarina Uttervall, Johanna Borg Bruchfeld, Charlotte Gran, et al.
European Journal of Haematology
|
September 6, 2022
Conditioning with melphalan 200 mg/m<sup>2</sup> and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care
Gabriel Afram, Roza Chaireti, Katarina Uttervall, et al.
Plos One
|
July 9, 2014
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment
Katarina Uttervall, Adil D Duru, Johan Lund, et al.
Plos One
|
September 18, 2015
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Adil Doganay Duru, Tolga Sutlu, Ann Wallblom, et al.
Cancer Medicine
|
April 23, 2024
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden
Katarina Uttervall, Love Tätting, Konstantinos Lemonakis, et al.
Cancer Medicine
|
November 3, 2023
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
Hareth Nahi, Gabriel Afram, Katarina Uttervall, et al.
European Journal of Haematology
|
January 20, 2021
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
Gabriel Afram, Katharina Helene Susek, Katarina Uttervall, et al.
Acta Haematologica
|
February 1, 2013
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis
Katarina Uttervall, Johannes Admasie, Evren Alici, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
European Journal of Haematology
|
September 6, 2019
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Charlotte Gran, Katarina Uttervall, Johanna Borg Bruchfeld, et al.
European Journal of Haematology
|
October 15, 2013
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients
Johan Lund, Katarina Uttervall, Johan Liwing, et al.
European Journal of Haematology
|
June 25, 2019
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Katarina Uttervall, Johanna Borg Bruchfeld, Charlotte Gran, et al.
European Journal of Haematology
|
September 6, 2022
Conditioning with melphalan 200 mg/m<sup>2</sup> and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care
Gabriel Afram, Roza Chaireti, Katarina Uttervall, et al.
Plos One
|
July 9, 2014
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment
Katarina Uttervall, Adil D Duru, Johan Lund, et al.
Plos One
|
September 18, 2015
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Adil Doganay Duru, Tolga Sutlu, Ann Wallblom, et al.
Cancer Medicine
|
April 23, 2024
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden
Katarina Uttervall, Love Tätting, Konstantinos Lemonakis, et al.
Cancer Medicine
|
November 3, 2023
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
Hareth Nahi, Gabriel Afram, Katarina Uttervall, et al.
European Journal of Haematology
|
January 20, 2021
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
Gabriel Afram, Katharina Helene Susek, Katarina Uttervall, et al.
Acta Haematologica
|
February 1, 2013
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis
Katarina Uttervall, Johannes Admasie, Evren Alici, et al.
Page
of 2